15 results about "Tubercle" patented technology

The utility model relates to the technical field of sample detection, in particular to a tubercle bacillus drug resistance comparison detection device which comprises a bottom plate, a control panel fixedly connected to the front side of the bottom plate, a first sliding groove formed in the top end of the bottom plate, a fixed base arranged at the top end of the bottom plate, a culture dish in contact with the top end of the fixed base and a clamping block slidably connected to the fixed base. The electric push rod is controlled to be started by operating the control panel, the sliding block is driven to move on the inner side of the first sliding groove through stretching of the sliding rod of the electric push rod, and the electric push rod is driven to move on the inner side of the first sliding groove. The slide block moves to drive the culture dish arranged at the top end of the fixed base fixed by the slide block to move, and the moved culture dish is consistent with the previous culture dish in position, so that a user can directly observe the difference between different culture dishes, and the time consumed for adjusting the microscope is shortened.

The invention relates to the technical field of biology, in particular to a protective monoclonal antibody targeting mycobacterium tuberculosis MPT83 as well as a preparation method and application of the protective monoclonal antibody. The antibody or an antigen binding fragment comprises a CDR sequence selected from at least one of the following sequences or a sequence with one amino acid substituted, deleted or increased: a heavy chain variable region CDR sequence: SEQ ID NO: 5-7; cDR sequences of a light chain variable region are as follows: SEQ ID NO: 9-10 and LAS. The monoclonal antibody 9C9 can be specifically combined with MPT83 protein on the surface of Mycobacterium tuberculosis (MTB) and shows efficient antituberculous activity in vivo and in vitro, the activity mainly comprises the aspects of remarkably enhancing the phagocytosis of macrophages on tubercle bacillus, inhibiting tubercle bacillus growth and the like, and in addition, the monoclonal antibody 9C9 is clear in sequence and structure, easy to develop and modify and capable of being used for preparing the anti-tubercle bacillus monoclonal antibody 9C9. The monoclonal antibody 9C9 disclosed by the invention has the advantages that the monoclonal antibody 9C9 can be used for preventing and treating tuberculosis, an immune-mediated treatment mechanism of the monoclonal antibody 9C9 does not easily induce pathogens to generate drug resistance, a new choice is provided for the treatment of tuberculosis when the monoclonal antibody 9C9 is applied to prevention and treatment of tuberculosis, an important technical basis is also provided for response of drug-resistant strains, development of diagnostic reagents, vaccine development and the like, and the application prospect is wide.

A diagnosis marker for pulmonary tuberculosis infection and a diagnosis kit thereof belong to the technical field of pulmonary tuberculosis diagnosis and treatment.The marker for detecting pulmonary tuberculosis provided by the present application is a LINC01148 gene, and the LINC01148 gene can be detected by primers to effectively diagnose whether a patient has pulmonary tuberculosis or not; the transcript sequence of the LINC01148 gene is SEQ ID NO.1, and the primer sequences of the LINC01148 gene are SEQ ID NO.2 and SEQ ID NO.3.Meanwhile, it is found that inhibiting the expression of the LINC01148 gene can effectively inhibit the activity of tubercle bacillus in macrophages, so the siRNA of the LINC01148 gene can be used for treating pulmonary tuberculosis.

The invention relates to the technical field of biology, in particular to a protective monoclonal antibody targeting Mycobacterium tuberculosis PspA and a preparation method and application thereof, the protective monoclonal antibody comprises at least one of the following CDR sequences or a sequence with one amino acid substituted, deleted or increased: a heavy chain variable region CDR sequence: SEQ ID NO: 4-6; the light chain variable region CDR sequences are as shown in SEQ ID NO: 8-9 and WAS. The antibody or the antigen binding fragment can specifically bind to PspA protein of mycobacterium tuberculosis (MTB), shows efficient antituberculous activity in vivo and in vitro, specifically, can significantly enhance phagocytosis of macrophages on tubercle bacillus, inhibit tubercle bacillus growth and the like, and is clear in sequence and structure, so that the antibody or the antigen binding fragment is easy to develop and transform, and has broad application prospects. And moreover, an immune-mediated treatment mechanism is not easy to induce pathogens to generate drug resistance, so that when being applied to prevention and treatment of tuberculosis, not only is a new choice provided for treatment of tuberculosis, but also an important basis is provided for response of drug-resistant strains, development of diagnostic reagents, vaccine development and the like, and the application prospect is wide.

The application discloses application of elvitegravir in preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria, and relates to the technical field of biological medicine.The application discloses, for the first time, that elvitegravir has the effect of inhibiting intracellular survival of mycobacterium tuberculosis or non-tuberculous mycobacteria at the level of macrophages, has the effect of anti-tuberculosis at the level of macrophages, and can be applied to preparation of an inhibitor of mycobacterium tuberculosis or non-tuberculous mycobacteria.The application also discloses that the anti-tuberculosis effect of elvitegravir at the level of macrophages is not the direct action of antibiotics on bacteria, but the inhibition of intracellular survival of tubercle bacillus by targeting and regulating host immune response, so that elvitegravir also has the potential of an immunomodulator, can realize the anti-tuberculosis effect by regulating the immune response of the body to tubercle bacillus infection, and is not affected by drug resistance of mycobacterium tuberculosis, and has a good treatment effect on multidrug-resistant tuberculosis.

The invention discloses a targeted sequencing primer composition for tuberculosis-related pathogens and a kit. The invention provides a mycobacterium tuberculosis targeting sequencing primer composition aiming at tuberculosis pathogens on the basis of a pathogen targeting sequencing technology. On the basis, a reliable basis is provided for better distinguishing tuberculosis from a'tuberculosis-like 'disease and clinical diagnosis and treatment of tuberculosis, non-tuberculosis mycobacteria and other pathogens capable of causing symptoms similar to tuberculosis after infection are incorporated, and a corresponding targeted sequencing primer composition and a kit are provided. The pathogens detected by the targeted sequencing primer composition and the kit for tuberculosis-related pathogens are relatively comprehensive, rapid and accurate screening and detection of mycobacterium tuberculosis and nontuberculosis mycobacterium infection are facilitated, and reliable basis can be provided for diagnosis and treatment of tuberculosis and other infection similar to tuberculosis; the important clinical significance is realized.

The application discloses a glycosylation modified polyethylene imine and application thereof as an anti-tuberculosis drug. The glycosylation modified polyethylene imine provided by the application is obtained by reacting polyethylene imine with gluconolactone, and one or more amino groups on the polyethylene imine are modified with a gluconolactone group L (HOCH2(CHOH)4CO-). Further, the anti-tuberculosis activity, cytotoxicity and stability of the glycosylation modified polyethylene imine are verified through a series of experiments, and the experimental results show that the toxicity of the gluconolactone modified polyethylene imine to normal cells is obviously reduced, the polyethylene imine has high inhibitory activity to tubercle bacillus, and the polyethylene imine has good stability, so the polyethylene imine has great clinical application potential as a new anti-tuberculosis drug.

The utility model relates to the technical field of medical teaching molds, and particularly discloses a teaching mold for tubercle bacillus skin test teaching, which comprises a shell and a induration simulation assembly, the shell is at least provided with a flexible diaphragm capable of covering the induration simulation assembly on the simulation working face, the flexible diaphragm is provided with a transparent area and measuring scales, and the displayable area of the transparent area is larger than the maximum size simulation induration on the induration simulation assembly; the hardening simulation assembly is movably assembled on one side of the flexible diaphragm, and the hardening simulation assembly can relatively displace under the action of external force by taking the transparent area on the flexible diaphragm as a reference; the hardening simulation assembly is provided with a substrate and a plurality of simulation hardening parts, the simulation hardening parts are fixed to the simulation working face of the substrate at intervals, and the interval arrangement track of the simulation hardening parts on the substrate corresponds to the displacement direction. The practical operation teaching of the system does not depend on actual tuberculosis infection detection personnel, the teaching process is basically not limited, and the system is flexible and practical.

The invention relates to the technical field of biological medicine, in particular to application of salvianolic acid in preparation of an anti-tuberculosis drug. The invention provides application of salvianolic acid A or pharmaceutically acceptable salt thereof in preparation of the anti-tuberculosis drug, the molecular formula of the salvianolic acid A is C26H22O10, and the structural formula is shown in formula I. When the salvianolic acid A is applied to preparation of the anti-tuberculosis drug, a brand new material basis is provided for research and development of the anti-tuberculosis drug, damage of the drug to normal tissues of a human body is reduced, and the anti-tuberculosis drug can be applied to preparation of the anti-tuberculosis drug. Toxic and side effects are reduced. From the aspect of action mechanism, the salvianolic acid A has various biological activities such as inflammation resistance, oxidation resistance and immunoregulation, and can inhibit the growth and reproduction of mycobacterium tuberculosis and enhance the immune defense capability of the body to tubercle bacillus through the multi-target synergistic effect, thereby achieving the purpose of treating tuberculosis.

The invention discloses a mycobacterium tuberculosis gene rapid screening service system oriented to a health physical examination center, and relates to the technical field of health services, and the mycobacterium tuberculosis gene rapid screening service system is characterized in that a sample is subjected to automatic uniform mixing and transfer to complete standardized pretreatment; the mechanical arm accurately loads the preprocessed sample to each independent channel of the micro-fluidic chip; bacterial lysis, nucleic acid adsorption, washing and elution are automatically completed in the sealed chip; the channels of the chip are subjected to thermal cycle amplification in parallel and generate target specific fluorescence signals; the system collects fluorescence intensity data of each channel in real time and automatically completes filtering and normalization processing; the trained deep learning model automatically analyzes a fluorescence curve and classifies results; and the system automatically generates an encrypted report and distributes the encrypted report to a subject and a health management center. By integrating closed parallel processing of the multi-channel micro-fluidic chip and fluorescence curve automatic analysis based on deep learning, automation and intelligentization of the whole process from sample loading to report generation can be realized.

The utility model relates to medical detection equipment technical field discloses a kind of mixing device based on tubercle bacillus drug sensitive detection, including storage bucket, the upper portion of the storage bucket is provided with sealing mechanism, the inside of the storage bucket is provided with storage mechanism, the storage mechanism includes motor, the bottom of the motor is fixedly installed in the inside bottom middle portion of storage bucket, the top of the motor is fixedly connected with the shaft of a steam turbine.The utility model drives the rotation of placing disc by bottom motor shaft, and stable mechanical power output can realize the efficient mixing of rotating sample and diluent, centrifugal force and eddy current effect are generated in rotation to promote liquid layering, accelerate uniform mixing, and motor speed is controllable, avoid traditional method to shake unevenly, shorten mixing time, directly reduce drug sensitive detection period, further applicable to high-throughput experimental environment, can support batch processing sample, also can integrate full-automatic detection system, reduce manual intervention, reach laboratory intelligent trend.

The invention relates to a medical sample collection instrument, and discloses a mycobacterium tuberculosis nucleic acid detection sputum sample collection device which comprises a collection pipe, a filter membrane is arranged in the collection pipe, a sealing mechanism is installed at the top of the collection pipe, an extraction mechanism is slidably connected to the top of the sealing mechanism, and the sealing mechanism comprises an opening and closing assembly. The opening and closing assembly comprises a cam disc and a pin shaft, an arc-shaped groove position is formed in the surface of the cam disc, the pin shaft is slidably connected to the inner wall of the inner arc-shaped groove position, a baffle is fixedly connected to the bottom of the pin shaft, a chassis is slidably connected to the bottom of the baffle, a sliding rail is arranged on the surface of the top of the chassis, and the baffle moves along the sliding rail. By means of the arc-shaped groove position structure on the surface of the cam disc, the traction pin shaft slides synchronously, then the baffle is driven to move front and back along the sliding rail at the bottom of the chassis, operation steps are greatly simplified, loading and taking out of samples can be completed more efficiently, and convenience of clinical operation is remarkably improved.

The invention relates to the technical field of biological medicine manufacturing, and discloses application of an HSPA5 monoclonal antibody in preparation of medicines for blocking tubercle bacillus transmission and / or resisting tuberculosis. The monoclonal antibody is adopted to antagonize the function of HSPA5 protein in a mouse body in a targeted manner, so that precise intervention on HSPA5 positive large vesicles secreted after neutrophil infection is realized, and the problems of survival and replication of mycobacterium tuberculosis in cells and subsequent intercellular, intertissue and individual propagation are solved.

The invention discloses an application of a compound JQB-22 or a pharmaceutically acceptable salt thereof in preparation of antituberculosis drugs, and relates to the technical field of biological medicines. It is found that the compound JQB-22 has the effect of inhibiting intracellular survival of tubercle bacillus at the macrophage level, the anti-tuberculosis effect can be remarkably enhanced by regulating and controlling host immunity, and compared with a traditional first-line anti-tuberculosis drug ethambutol, the compound JQB-22 shows better control over the load of tubercle bacillus in lung tissue. The compound JQB-22 provided by the invention has the potential of being developed as an antituberculous drug. The invention provides an innovative research direction and a preclinical candidate drug for solving the treatment difficulty of the drug-resistant tuberculosis.

The invention relates to the technical field of biological medicine manufacturing, and discloses application of an HSPA5 monoclonal antibody in preparation of medicines for blocking tubercle bacillus transmission and / or resisting tuberculosis. The monoclonal antibody is adopted to antagonize the function of HSPA5 protein in a mouse body in a targeted manner, so that precise intervention on HSPA5 positive large vesicles secreted after neutrophil infection is realized, and the problems of survival and replication of mycobacterium tuberculosis in cells and subsequent intercellular, intertissue and individual propagation are solved.